Treats bronchoconstriction. ANDA 218156, held by LEXENPHARM. Arformoterol Tartrate.
As of Nov 21, 2026, ANDA 218156 (Arformoterol Tartrate), held by LEXENPHARM, was first approved by FDA on Nov 18, 2024, with 0 approved supplements and 0 published complete response letters.
Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2, 5.2 ) Arformoterol tartrate inhalation solution is not indicated to treat asthma. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Arformoterol TartrateEQ 0.015MG BASE/2ML · solution;inhalation | Arformoterol Tartrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters